{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:35:13Z","timestamp":1791819313349,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"FRANCE EXCELLENCE SCHOLARSHIPS PROGRAM"},{"name":"ITMO cancer , France","award":["C21033AS"],"award-info":[{"award-number":["C21033AS"]}]},{"name":"Amidex Fondation \u201cInterdisciplinarity\u201d","award":["mRNAnanoPSMA"],"award-info":[{"award-number":["mRNAnanoPSMA"]}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["R22030AA"],"award-info":[{"award-number":["R22030AA"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Castration-resistant prostate cancer (CRPC) is an advanced and ultimately incurable stage of the disease that arises despite androgen deprivation and remains challenging to treat due to the limited and short-lived efficacy of current therapies. Heat shock protein 27 (HSP27), a molecular chaperone, has been implicated in prostate cancer (PC) progression and therapy resistance; however, its mechanistic roles remain incompletely understood. This study aimed to delineate the HSP27 interactome in PC cells during PC progression and to explore its functional significance, particularly in relation to the mTOR signaling pathway, which is activated in most cases, primarily due to PTEN loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed affinity purification-mass spectrometry (AP-MS) to identify HSP27-interacting proteins in a panel of prostate cell lines with increasing aggressiveness: PNT1A (non-malignant), LNCaP (androgen-sensitive), DU-145, and PC-3 (both androgen-independent CRPC models). Functional enrichment and network analyses were conducted to uncover pathways associated with HSP27 interactors. Validation experiments included Western blotting, co-immunoprecipitation, and pharmacological inhibition using OGX-427 and mTOR inhibitors (Everolimus, Sapanisertib) in prostate cancer cell lines, patient-derived organoids (PDOs), and xenograft models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HSP27 exhibited a progressively expanded interactome in CRPC models, with enrichment of proteins involved in stress adaptation, proteostasis, and mTOR signaling. These insights highlight HSP27 not only as a molecular chaperone but also as a dynamic network hub that may promotes survival in stress-adapted tumor states. In PC-3 cells, HSP27 stabilized key mTORC1 components, including RAPTOR, S6K1, and 4E-BP1 via its chaperone function, thereby enhancing mTORC1 activation. Combined inhibition of HSP27 using the antisense oligonucleotide OGX-427 (Apatorsen) and mTOR blockade via Sapanisertib induced a robust synergistic anti-tumor effect across diverse preclinical models, including advanced PC Patient-derived organoid (PDOs) and CRPC xenografts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings reveal novel insights into HSP27\u2019s role in PC progression and its modulation of the mTOR signaling pathway in CRPC, highlighting dual HSP27\/mTOR inhibition as a promising therapeutic approach for advanced, treatment-resistant disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03695-6","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:35:43Z","timestamp":1774398943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["HSP27 functional switch drives castration-resistant prostate cancer via mTOR pathway activation, highlighting promising combination therapies"],"prefix":"10.1186","volume":"45","author":[{"given":"Quang Hieu","family":"Duong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Khanh","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Thom","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Audebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Camoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngan Giang","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baboudjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Giusiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uyen Thi Tu","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souhaila","family":"Zaghdoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Adelaide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Baylot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gleave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ta\u00efeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palma","family":"Rocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"3695_CR1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, Feng F, Gillessen S, Ali SA, et al. The lancet commission on prostate cancer: planning for the surge in cases. Lancet Lond Engl. 2024;403:1683\u2013722.","journal-title":"Lancet Lond Engl"},{"key":"3695_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3695_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121\u201331 (Massachusetts Medical Society).","journal-title":"N Engl J Med."},{"key":"3695_CR4","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet Elsevier. 2022;399:1695\u2013707.","journal-title":"Lancet Elsevier"},{"key":"3695_CR5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386:1132\u201342 (Massachusetts Medical Society).","journal-title":"N Engl J Med."},{"key":"3695_CR6","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.euf.2023.03.024","volume":"9","author":"B Hoeh","year":"2023","unstructured":"Hoeh B, Garcia CC, Wenzel M, Tian Z, Tilki D, Steuber T, et al. Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer: updated network meta-analysis stratified by disease volume. Eur Urol Focus Elsevier. 2023;9:838\u201342.","journal-title":"Eur Urol Focus Elsevier"},{"key":"3695_CR7","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.3390\/cancers15205047","volume":"15","author":"TK Le","year":"2023","unstructured":"Le TK, Duong QH, Baylot V, Fargette C, Baboudjian M, Colleaux L, et al. Castration-resistant prostate cancer: from uncovered resistance mechanisms to current treatments. Cancers. 2023;15:5047 (Multidisciplinary Digital Publishing Institute).","journal-title":"Cancers."},{"key":"3695_CR8","doi-asserted-by":"publisher","first-page":"6595","DOI":"10.1158\/0008-5472.CAN-03-3998","volume":"64","author":"P Rocchi","year":"2004","unstructured":"Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res. 2004;64:6595\u2013602.","journal-title":"Cancer Res"},{"key":"3695_CR9","doi-asserted-by":"publisher","first-page":"11083","DOI":"10.1158\/0008-5472.CAN-05-1840","volume":"65","author":"P Rocchi","year":"2005","unstructured":"Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3\u2013mediated suppression of apoptosis. Cancer Res. 2005;65:11083\u201393.","journal-title":"Cancer Res"},{"key":"3695_CR10","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/j.1464-410X.2006.06425.x","volume":"98","author":"P Rocchi","year":"2006","unstructured":"Rocchi P, Jugpal P, So A, Sinneman S, Ettinger S, Fazli L, et al. Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. BJU Int. 2006;98:1082\u20139.","journal-title":"BJU Int"},{"key":"3695_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s10637-017-0553-x","volume":"36","author":"EY Yu","year":"2018","unstructured":"Yu EY, Ellard SL, Hotte SJ, Gingerich JR, Joshua AM, Gleave ME, et al. A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. Invest New Drugs. 2018;36:278\u201387.","journal-title":"Invest New Drugs"},{"key":"3695_CR12","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1038\/mt.2012.155","volume":"20","author":"V Baylot","year":"2012","unstructured":"Baylot V, Katsogiannou M, Andrieu C, Taieb D, Acunzo J, Giusiano S, et al. Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer. Mol Ther. 2012;20:2244\u201356.","journal-title":"Mol Ther"},{"key":"3695_CR13","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1038\/onc.2009.479","volume":"29","author":"C Andrieu","year":"2010","unstructured":"Andrieu C, Taieb D, Baylot V, Ettinger S, Soubeyran P, De-Thonel A, et al. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene. 2010;29:1883\u201396.","journal-title":"Oncogene"},{"key":"3695_CR14","doi-asserted-by":"crossref","unstructured":"Cherif C, Nguyen DT, Paris C, Le TK, Sefiane T, Carbuccia N, et al. Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. Oncogene. 2021;41:125\u201337.","DOI":"10.1038\/s41388-021-02039-2"},{"key":"3695_CR15","unstructured":"Le TK, Cherif C, Omabe K, Paris C, Lannes F, Audebert S, et al. DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer. Mol Ther. 2022. Available from:\u00a0https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1525001622004932. Cited 2022 Nov 15"},{"key":"3695_CR16","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1074\/mcp.M114.041228","volume":"13","author":"M Katsogiannou","year":"2014","unstructured":"Katsogiannou M, Andrieu C, Baylot V, Baudot A, Dusetti NJ, Gayet O, et al. The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets. Mol Cell Proteomics MCP. 2014;13:3585\u2013601.","journal-title":"Mol Cell Proteomics MCP"},{"key":"3695_CR17","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3390\/biomedicines9070795","volume":"9","author":"DT Nguyen","year":"2021","unstructured":"Nguyen DT, Le TK, Paris C, Cherif C, Audebert S, Udu-Ituma SO, et al. Antisense oligonucleotide-based therapeutic against menin for triple-negative breast cancer treatment. Biomedicines. 2021;9:795 (Multidisciplinary Digital Publishing Institute).","journal-title":"Biomedicines."},{"key":"3695_CR18","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/nprot.2006.288","volume":"1","author":"M Chevallet","year":"2006","unstructured":"Chevallet M, Luche S, Rabilloud T. Silver staining of proteins in polyacrylamide gels. Nat Protoc. 2006;1:1852\u20138.","journal-title":"Nat Protoc"},{"key":"3695_CR19","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1074\/mcp.M113.031591","volume":"13","author":"J Cox","year":"2014","unstructured":"Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction. Termed MaxLFQ Mol Cell Proteomics MCP. 2014;13:2513\u201326.","journal-title":"Termed MaxLFQ Mol Cell Proteomics MCP"},{"key":"3695_CR20","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008;26:1367\u201372.","journal-title":"Nat Biotechnol"},{"key":"3695_CR21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","volume":"174","author":"DA Quigley","year":"2018","unstructured":"Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell Elsevier. 2018;174:758-769.e9.","journal-title":"Cell Elsevier"},{"key":"3695_CR22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT Method. Methods. 2001;25:402\u20138.\u00a0Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1046202301912629. Cited 2023 Apr 24","journal-title":"Methods"},{"key":"3695_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nprot.2016.006","volume":"11","author":"J Drost","year":"2016","unstructured":"Drost J, Karthaus WR, Gao D, Driehuis E, Sawyers CL, Chen Y, et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat Protoc. 2016;11:347\u201358.","journal-title":"Nat Protoc"},{"key":"3695_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3892\/ol.2021.13124","volume":"23","author":"K Cheaito","year":"2021","unstructured":"Cheaito K, Bahmad H, Hadadeh O, Msheik H, Monzer A, Ballout F, et al. Establishment and characterization of prostate organoids from treatment-na\u00efve patients with prostate cancer. Oncol Lett. 2021;23:6.","journal-title":"Oncol Lett"},{"key":"3695_CR25","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"3695_CR26","doi-asserted-by":"crossref","unstructured":"Wu X, Gong S, Roy-Burman P, Lee P, Culig Z. Current mouse and cell models in prostate cancer research. 2013. Available from:\u00a0https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/20\/4\/R155.xml. Cited 2025 Feb 11","DOI":"10.1530\/ERC-12-0285"},{"key":"3695_CR27","doi-asserted-by":"publisher","first-page":"e21800","DOI":"10.1371\/journal.pone.0021800","volume":"6","author":"F Supek","year":"2011","unstructured":"Supek F, Bo\u0161njak M, \u0160kunca N, \u0160muc T. REVIGO summarizes and visualizes long lists of gene ontology terms. PLOS ONE. 2011;6:e21800 (Public Library of Science).","journal-title":"PLOS ONE"},{"key":"3695_CR28","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/j.biocel.2012.06.005","volume":"44","author":"HH Kampinga","year":"2012","unstructured":"Kampinga HH, Garrido C. HSPBs: small proteins with big implications in human disease. Int J Biochem Cell Biol. 2012;44:1706\u201310.","journal-title":"Int J Biochem Cell Biol"},{"key":"3695_CR29","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.4161\/cc.5.22.3448","volume":"5","author":"C Garrido","year":"2006","unstructured":"Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle Georget Tex. 2006;5:2592\u2013601.","journal-title":"Cell Cycle Georget Tex"},{"key":"3695_CR30","doi-asserted-by":"publisher","first-page":"100502","DOI":"10.1016\/j.xcrm.2021.100502","volume":"3","author":"MA Rice","year":"2022","unstructured":"Rice MA, Kumar V, Tailor D, Garcia-Marques FJ, Hsu E-C, Liu S, et al. SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer. Cell Rep Med. 2022;3:100502.","journal-title":"Cell Rep Med"},{"key":"3695_CR31","first-page":"1","volume":"8","author":"V Panwar","year":"2023","unstructured":"Panwar V, Singh A, Bhatt M, Tonk RK, Azizov S, Raza AS, et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduct Target Ther. 2023;8:1\u201325 (Nature Publishing Group).","journal-title":"Signal Transduct Target Ther."},{"key":"3695_CR32","doi-asserted-by":"publisher","first-page":"11088","DOI":"10.3390\/ijms222011088","volume":"22","author":"T Pungsrinont","year":"2021","unstructured":"Pungsrinont T, Kallenbach J, Baniahmad A. Role of PI3K-AKT-mTOR Pathway as a pro-survival signaling and resistance-mediating mechanism to therapy of prostate cancer. Int J Mol Sci. 2021;22:11088.\u00a0Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8538152\/. Cited 2023 Apr 19","journal-title":"Int J Mol Sci."},{"key":"3695_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11\u201322.","journal-title":"Cancer Cell"},{"key":"3695_CR34","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.3892\/mmr.2014.2630","volume":"10","author":"D Li","year":"2014","unstructured":"Li D, Zhao LN, Zheng XL, Lin P, Lin F, Li Y, et al. Sox2 is involved in paclitaxel resistance of the prostate cancer cell line PC-3 via the PI3K\/Akt pathway. Mol Med Rep. 2014;10:3169\u201376.","journal-title":"Mol Med Rep"},{"key":"3695_CR35","first-page":"2021","volume":"19","author":"Z Liu","year":"2020","unstructured":"Liu Z, Liu Y, Long Y, Liu B, Wang X. Role of HSP27 in the multidrug sensitivity and resistance of colon cancer cells. Oncol Lett. 2020;19:2021\u20137.","journal-title":"Oncol Lett"},{"key":"3695_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","volume":"19","author":"J Li","year":"2014","unstructured":"Li J, Kim SG, Blenis J. Rapamycin: one drug, many effects. Cell Metab\u00a0Elsevier. 2014;19:373\u20139.\u00a0Available from: https:\/\/www.cell.com\/cell-metabolism\/abstract\/S1550-4131(14)00007-2. Cited 2023 Apr 19","journal-title":"Cell Metab\u00a0Elsevier"},{"key":"3695_CR37","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1356-9597.2004.00727.x","volume":"9","author":"N Oshiro","year":"2004","unstructured":"Oshiro N, Yoshino K, Hidayat S, Tokunaga C, Hara K, Eguchi S, et al. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells Devoted Mol Cell Mech. 2004;9:359\u201366.","journal-title":"Genes Cells Devoted Mol Cell Mech"},{"key":"3695_CR38","doi-asserted-by":"publisher","first-page":"102886","DOI":"10.1016\/j.critrevonc.2020.102886","volume":"147","author":"L Formisano","year":"2020","unstructured":"Formisano L, Napolitano F, Rosa R, D\u2019Amato V, Servetto A, Marciano R, et al. Mechanisms of resistance to mTOR inhibitors. Crit Rev Oncol Hematol. 2020;147:102886.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3695_CR39","doi-asserted-by":"publisher","first-page":"17414","DOI":"10.1073\/pnas.0809136105","volume":"105","author":"AY Choo","year":"2008","unstructured":"Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci. 2008;105:17414\u20139 (Proceedings of the National Academy of Sciences).","journal-title":"Proc Natl Acad Sci."}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03695-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03695-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03695-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:48:24Z","timestamp":1781642904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03695-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3695"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03695-6","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tumor tissue samples from patients with prostate cancer were collected as part of routine clinical care, without deviation from guidelines. Patients provided written informed consent, which was recorded in their medical records, and were informed that the samples could be used for research purposes. All procedures were performed in accordance with the Helsinki and Istanbul declarations. The collection of tumours was approved by the Biological Resource Centre (BCR) of the Marseille Public Hospital System (identification number: 0CPREP01E001). The BCR has been certified since 8 December 2023 according to ISO 9001 and ISO 20387 standards and is authorized to provide biological resources for research projects by the French Ministry of Higher Education, Research and Innovation. Data were collected prospectively and anonymously in a dedicated database accessible only to authorized authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests. The University of British Columbia has submitted patent applications on Apatorsen, an antisense inhibitor of HSP27, listing PR as an inventor. This IP has been licensed to OncoGenex Technologies, a Vancouver-based biotechnology company. P.R and D.T are cofounders of SilonTx (https:\/\/silontx.com), a biotech company started in April 2024 focusing on precision medicine and nucleic acid therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}